Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...

Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...

Earlier, Dr. Patni was Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals, until their acquisitions by larger companies. He also held roles of ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B. Anthos ...

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025.

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we ...

Novartis (NVS) on Tuesday agreed to acquire biopharmaceutical firm Anthos Therapeutics in a deal worth up to $3.1 billion, as the Swiss pharmaceutical giant looks to boost its cardiovascular portfolio ...

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...

The merger is the second involving an SCD therapy developer in the last few weeks, coming after Pfizer agreed a $5.4 billion takeover of Global Blood Therapeutics and its oral therapy Oxbryta ...